A

new analysis finds that a notable portion of treatment guidelines issued in recent years by medical societies and government agencies for combating mild depression were compiled by individuals with financial conflicts of interest or lacked other safeguards to ensure impartiality.

Of 172 people who participated in 14 guidelines committees, 18 percent had ties to drug makers that sell antidepressants, and some had connections to more than one company. Five guidelines, meanwhile, recommended antidepressants as a first-line treatment for mild depression, and four of those — or 80 percent — had panelists with some type of financial connection, according to the analysis in Psychotherapy and Psychosomatics.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Most antidepressants are prescribed by primary care physicians most of whom don’t know the first thing about psychopharmacology. The patients often wind up seeing the shrink due to medication mismanagemen by the idiot GP who produces an iatrogenic serotoninergic crisis because they were unaware of the taper guidelines for SSRI’s.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy